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Abstract
Background: The increasing incidence of hepatocellular carcinoma in Western countries has led to an expanding
interest of scientific research in this field. Therefore, a vast need of experimental models that mimic the natural
pathogenesis of hepatocellular carcinoma (HCC) in a short time period is present. The goal of our study was (1) to
develop an efficient mouse model for HCC research, in which tumours develop in a natural background of fibrosis
and (2) to assess the time-dependent angiogenic changes in the pathogenesis of HCC.
Methods: Weekly intraperitoneal injections with the hepatocarcinogenic compound N-nitrosodiethylamine was
applied as induction method and samples were taken at several time points to assess the angiogenic changes
during the progression of HCC.
Results: The N-nitrosodiethylamine-induced mouse model provides well vascularised orthotopic tumours after
25 weeks. It is a representative model for human HCC and can serve as an excellent platform for the development
of new therapeutic targets.
Introduction
An efficient and representative mouse model is the cor-
nerstone of a successful experiment. The growing inci-
dence of hepatocellular carcinoma (HCC) in Western
countries has resulted in an expanding interest of scien-
tific research in this field. Therefore, a vast need of
experimental models that mimic the natural pathogen-
esis of HCC in a short time period is present.
Several genetically modified mouse models (GMM)
develop HCC in relatively short time periods. They
often represent only one or a few specific mutation(s),
while natural tumours are a dynamic environment con-
sisting of a heterogenic cell population with different
genotypes, which change over time as a response to
variable external conditions [1-3]. Xenograft models are
relevant for fast drug screening and proof-of-principle
experiments [4], but face similar limitations as the
GMMs, since only one cell phenotype is assessed, while
tumours exist of a large variety of phenotypes. Results
should always be interpreted with care, because introdu-
cing foreign cells in an animal system, as done in a
xenograft mouse model, creates an altered physiological
interaction between tumour and environment [5], lead-
ing to spectacular results that can seldom be confirmed
in cancer patients [6].
A compound often used for the chemical induction of
HCC is N-nitrosodiethylamine (DEN). DEN is metabo-
lised by cytochrome P450 enzymes, which are abun-
dantly present in the liver, leading to the formation of
the reactive ethyl diazonium ion [7]. The latter holds
the potential to alkylate DNA structures, causing altera-
tions in the expression levels of tumour promoting and/
or suppressing genes [8]. Single injections of DEN,
sometimes in combination with phenobarbital treat-
ment, are frequently used for the induction of HCC in
mice and rats and have been validated as a genetically
representative model for human HCC [9]. However, it
does not induce fibrosis.
The goal of our study was (1) to develop an efficient
mouse model for hepatocellular carcinoma (HCC)
research, in which HCC develops in a natural back-
ground of fibrosis and (2) to assess the time-dependent
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angiogenic changes in the pathogenesis of HCC [10,11]
since anti-angiogenic molecules are currently a hot topic
in research concerning therapies for non-resectable
HCC [12-14].
Materials and methods
Animals
4-week-old male mice (129S2/SvPasCrl) were purchased
from Charles River laboratories (Brussels, Belgium).
They were kept under constant temperature and humid-
ity in a 12 h controlled dark/light cycle. Mice were fed
ad libitum on a standard pellet diet. The Ethical Com-
mittee of experimental animals at the Faculty of Medi-
cine and Health Sciences, Ghent University, Belgium,
approved the protocols.
HCC induction
5-week-old male mice (n = 45) received intraperitoneal
injections once per week with DEN (35 mg/kg body-
weight) diluted in saline using a 0,5 mL syringe with a
29G needle. If mice suffered from weight loss ≥15%
compared to the previous week, an injection was
omitted. The control group was injected with an equal
volume of saline and injections were randomly passed
over in a comparable quantity as in the DEN-group.
Tissue sampling & histology
After 4, 16, 20, 25 and 30 weeks, 8 animals per group
were sacrificed under isoflurane (Forene®) anaesthesia
while blood was obtained from the carotic artery. After
macroscopic evaluation, all organs were sampled in 4%
phosphate buffered formaldehyde (Klinipath, ref:
4078.9020) and embedded in paraffin. HCC-lesions and
non-HCC-tissue were separately collected and snap fro-
zen in liquid nitrogen. Haematoxilin-eosin staining
(H&E) was performed to evaluate the morphological
changes inflicted by the DEN-treatment. Sirius Red
staining was carried out to score the fibrotic stage of the
liver. Reticulin staining was performed to help identify-
ing HCC-nodules. All stainings were done using stan-
dard histology protocols and evaluated by an
experienced pathologist.
Immunohistochemistry
Immunohistochemical stainings (IHC) were used to
quantify protein expression levels inside HCC-nodules,
tissue surrounding HCC-nodules and non-HCC tissue.
As a marker for angiogenesis specific monoclonal anti-
bodies were used against vascular endothelial growth
factor (VEGF) (Santa Cruz biotechnology, ref sc-152),
CD105 (R&D systems, ref AF1320) and Tie2 (BD
Bioscience, ref 557039). Tumour hypoxia was evaluated
by staining for hypoxia inducible factor 1 alpha (HIF1a)
(Santa Cruz ref sc-53546) and macrophages were
visualised using F4/80-staining (AbD serotec, ref
MCA497G). A negative marker for HCC, Fatty Acid
Binding Protein (FABP, Hycult biotechnology, ref
HP8010) was used [15]. Stainings were performed as
previously described [15-17] and were semi-quantita-
tively measured by Olympus CellD software. Intercapil-
lary distance (ICD) was used as a marker for
microvessel density, by measuring the average distance
between vessels in HCC-nodules on CD105-stained
slides.
Medical imaging
Additional in vivo tests were performed using microPET
imaging as non-invasive technology. The latter acquisi-
tions were performed using a GE FLEX Triumph micro-
PET/SPECT/CT scanner (Gamma Medica-Ideas). This
state-of-the-art scanner consists of a micro-PET module
(LabPET8) with 2’2’10 mm3 LYSO/LGSO scintillators in
an 8-pixel, quad-APD detector module arrangement.
This system is capable of delivering 1 mm spatial resolu-
tion in rodents at a sensitivity of 4%, thereby covering a
field-of-view of 10 cm transaxially by 8 cm axially, while
the CT part can scan structures down to 10-15 μm. The
micro-CT part consists of a high-resolution micro-CT
tube with a focal spot size switchable between 10 or
50 μm, combined with a flat-panel CsI detector.
Animals were injected with 18,5 mBq of [18F]- fluoro-
methylcholine ([18F]FMCH) (Laboratory of Radiophar-
macy, Ghent, Belgium) [18,19] immediately prior to
their microPET scan on the camera bed at the start of a
dynamic acquisition. Frames of 15×20 sec and 5×5 min
were accordingly sequentially recorded. For anatomical
localisation, a microCT-scan was sequentially acquired
using 256 projections over 360 degrees at 70 kVp/
180 μA and 1,3 magnification with a spot size of 50 μm.
This results in a scanning time below 2 minutes, whilst
keeping the radiation dose at 20 - 25 mGy. This radia-
tion dose is sufficiently low enough to allow for follow-
up studies. The resulting PET data were reconstructed
using 30 iterations of the Maximum Likelihood Expecta-
tion Maximisation algorithm in 160×160×63 images of
0,5 × 0,5 × 1,175 mm voxel size and no posteriori 3D fil-
tering was applied. CT-reconstruction was straightfor-
ward analytical. All images were fused and analysed
with VIVID (Amira ®, San diego, USA).
Vascular corrosion casts (VCC) were obtained by per-
fusing Batson n°17 (Polysciences ref: 07349) through the
aorta (arterial casts) or vena ileocolica (venous cast); and
dissolving soft tissue in KOH. The VCC were then
scanned in the micro-CT scanner, after which the
reconstructed dataset was segmented before generating
3D surface models. In order to assess the VCC with
scanning electron microscopy (SEM), the relevant parts
were cut off and coated with platinum.
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Protein expression
Alterations in protein expression levels of angiogenic
factors in HCC-tissue were measured by ELISA [20].
Placental growth factor (PlGF) (Mouse PlGF-2 Quanti-
kine ELISA Kit, R&D Biosystems) and VEGF (Mouse
VEGF Quantikine ELISA Kit, R&D Systems) were
measured in liver tissue and in serum. Protein levels of
soluble VEGF receptor 1 (sVEGFR1) (Mouse sVEGF R1/
Flt-1 Quantikine ELISA Kit R&D Biosystems) were mea-
sured in serum. To normalise the total protein concen-
tration in the samples, a normalisation factor was
determined by a Biorad RC/DC Protein Assay kit.
Statistics
Data were statistically analysed with SPSS 16. Datasets
were tested for normality using the Kolmogorov-Smir-
nov test before further analysis. Parametric data were
subjected to a student’s t-test to evaluate the difference
between the DEN and control group. Data that did not
show a normal distribution were tested with the non-
parametric Mann-Whitney-U test. A p value of < 0.05
was considered statistically significant. Correlations were
calculated using the Pearson correlation test.
Results
Macroscopic evaluation
Significant lower weight (p < 0,001) was observed
between adult DEN-mice (25,26 g (± 0,49)) and control
mice (31,28 g (± 0,91)) at 25W. Macroscopic evaluation
of the liver revealed tumours at 20W (2,6 (± 2,66)
tumours/liver), 25W (6,81 (± 1,69) tumours/liver) and
30W (12,9 (± 2,17) tumours/liver) (figure 1).
Microscopic evaluation
HCC progression
H&E staining showed dysplastic changes at 20W, 25W
and 30W. Small cell dysplasia was frequently found
throughout the liver and readily distinguishable nodules
of neoplasia were seen at 25W and 30W (figure 2).
These nodules were confirmed as HCC using reticulin
staining and HE (and immunohistochemistry for FABP).
HCC nodules were identified and measured on reticulin
Figure 1 Macroscopic HCC-lesions at different time points throughout the experiment. Asterisks (*) represent the significant P-values of
the control group compared to DEN-groups (** = p < 0,01 and *** = p < 0,001).
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and H&E stained histological slides. Tumour burden
(size × number) increased significantly during DEN-
treatment (figure 2). Sirius red staining demonstrated
the fibrotic action of DEN, with time-dependent
increase of Metavir-score (figure 3), while controls did
not show any fibrotic septa.
A time-dependent increase in FABP-negative spots was seen
throughout the experiment (figure 4). While parts of the liver
were FABP-negative, some hepatocytes had an increased
FABP-expression in the DEN-treated groups whereas control
livers showed a homogenous expression (figure 4). FABP (p <
0,001) was significantly down regulated in all the DEN-treated
groups compared to the control group (figure 4).
Inflammation and fibrosis
The number and size of inflammatory foci significantly
increases after 20W (p < 0,001 and p < 0,05), 25W (p <
0,001 and p < 0,05) and 30W DEN (p < 0,001 and p <
0,05) compared to control livers (figure 3 and 5). This
was accompanied by an increased abundance of Kuppfer
cells in and around HCC, as well as in non-HCC tissue
(figure 3). Compared to non-HCC tissue, the expression
of F4/80 was significantly up-regulated after 16W (p <
0,01), 20W (p < 0,05), 25W (p < 0,001) and 30W (p <
0,001) in HCC, and in the surrounding matrix of HCC-
lesions (p < 0,001) (figure 5).
Angiogenesis
VEGF expression was more promintent inside HCC-
nodules (figure 6 and 7) than in the surrounding matrix,
yet both were significantly increased (p < 0,01) after
20W, 25W and 30W DEN compared to adjacant non-
HCC tissue. VEGF-levels were significantly increased
inside HCC-nodules compared to controls after 25W
(p < 0,05) and 30W DEN (p < 0,05) (table 1). The expres-
sion of VEGF was correlated (r = 0,68, p < 0,001) with
HIF1-a levels. HIF1a levels were significantly up-regu-
lated in and around tumour tissue at 20W (p < 0,001),
25W (in: p < 0,001; around: p < 0,05) and 30W DEN (p <
0,001) compared to adjacant non-HCC tissue (figure 6
and 7). Non-HCC tissue was hypoxic after 16W (p <
0,01), 25W (p < 0,01) and 30W (p < 0,001) of DEN com-
pared to healthy controls (table 1). The increased HIF1a
expression was more prominent inside HCC nodules
than in surrounding matrix (figure 6), the latter being
characterised by a major increase in vascularisation after
20W, 25W and 30W of DEN compared to non-tumour
tissue (p < 0,001). CD105 was also increased inside HCC-
lesions after 20W (p < 0,05), 25W (p < 0,001) and 30W
(p < 0,01) (figure 6 and 7), implicating an increased intra-
tumoral neovascularisation, confirmed by ICD (figure 8).
The ICD decreased at 20W and 25W, verifing
Figure 2 Mean HCC burden (size × number tumours) at different time points and representative pictures of H&E stained HCC-nodules.
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Figure 3 Representative pictures of fibrosis in non-tumorous tissue on sirius red staining (top), inflammatory foci on H&E staining
(middle) and macrophages on F4/80 immunohistochemistry (bottom).
Figure 4 Percentage of FABP-negative sites and representative pictures of the IHC staining. Asterisks (*) represent the significant p-value
of the control group compared to DEN-groups (*** = p < 0,001).
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neovascularisation; an increase was seen at 30W (figure
8). Differences of ICD were statistically significant
between all groups (p < 0,001). DEN-induced HCC-
lesions showed an increased expression of Tie2 which
was higher in HCC-surrounding tissue than inside HCC-
nodules (figure 6). Tie2 was significantly up-regulated
around HCC after 20W (p < 0,01), 25W (p < 0,001) and
30W (p < 0,01) compared to non-HCC tissue, and inside
HCC after 25W (p < 0,001) and 30W DEN (p < 0,01 (fig-
ure 7, table 1). Tie2 expression was correlated (r = 0,58,
p < 0,001) with macrophage recruitment (F4/80-staining).
Medical imaging
Preliminary results, illustrated by Figure 9 suggest that
these tumours could be visualised by [18F]FMCH PET
imaging; and that this technique is useful for follow up
Figure 5 Top: mean number (left) and size (right) of inflammatory foci at different time points; Bottom: expression of F4/80 on
immunohistochemistry. Asterisks (*) represent the significant P-value of the difference between expression inside and around HCC-nodules
compared to non-tumour tissue in DEN-treated livers (* = p < 0,05, ** = p < 0,01, *** = p < 0,001).
Heindryckx et al. Molecular Cancer 2010, 9:219
http://www.molecular-cancer.com/content/9/1/219
Page 6 of 14
studies. A short follow study (25W - 35W) was con-
ducted on mice. An increased uptake was seen at the
sequential measurements, which correlates with their
increased tumour burden. However, further confirma-
tion in larger groups is needed.
The combination of VCC and CT-scanning revealed
the chaotic pattern and dishierarchical organisation of
tumour vessels (figure 10). The SEM-images provide
further insight in the microvasculature (figure 10),
showing the tumour vessel abnormality and visualising
two mechanisms of neovascularisation, pruning and
intussusceptive angiogenesis (figure 11).
Protein expression
PlGF and VEGF are important factors involved in
tumour angiogenesis and were significantly up-regulated
in liver tissue at 16W (respectively p < 0,05 and p <
0,001), 20W (p < 0,05 and p < 0,01) and tumour tissue
Healthy liver 20W DEN 30W DEN
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Figure 6 Representative pictures of immunohistochemical stainings for Tie2, VEGF, HIF1a and CD105 in healthy liver, 20W DEN
(tumour tissue) and 30W DEN (tumour tissue).
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samples at 25W DEN (p < 0,05 and p < 0,01). The up-
regulation of PlGF was more prominent in tumour tis-
sue at 30W with an average of 422,28 pg/mg (± 76,99)
PlGF compared to the 2,90 pg/mg (± 0,77) PlGF
detected in the control group (p < 0,001) (figure 12).
In serum, the PlGF protein levels were significantly
up-regulated at 16W (p < 0,05), 25W (p < 0,05) and
30W (p < 0,01) with similar results as seen in liver tis-
sue (figure 12). VEGF levels were up-regulated at 25W
(p < 0,05) and 30W (p < 0,05). There was a slight
increase of sVEGFR1 at 30W DEN treatment, but no
significant difference was seen between controls and
25W DEN (figure 12).
Discussion
Animal models can provide essential knowledge about
the pathogenesis of hepatocellular carcinoma, particu-
larly when they mimic the tissue environment in which
human tumours develop. N-nitrosodiethylamine has
been shown to induce tumours which are molecularly
similar to human HCC with poor prognosis [9]. Yet, the
major drawback is the long time needed for tumour
progression, it can take over one year for tumours to
develop [21-26]. The macroscopic and microscopic eva-
luation of tumours, PET-CT images and histopathologi-
cal analysis confirmed the presence of HCC after 25
weeks. While most DEN-induced models take at least 1
Figure 7 Top: Tie2 epxression (left) and VEGF expression (right); Bottom: HIF1-a (left) and CD105 (right). Asterisks (*) represent the
significant P-value of the difference between expression inside and around HCC-nodules compared to non-tumour tissue in DEN-treated livers
(* = p < 0,05, ** = p < 0,01, *** = p < 0,001).
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year to develop tumours, weekly intraperitoneal injec-
tions with 35 mg/kg DEN give rise to relatively fast
tumour occurrence in a background of fibrosis. Since
HCC is known to be a hypervascularised tumour, and
recent therapies have focused on inhibiting angiogenesis,
we have studied the time-dependent changes in angio-
genic and inflammatory factors in this mouse model.
Previous studies with several DEN-induced rat and
mice models, have shown that the expression level of
FABP is decreased in DEN-induced liver lesions [15,27].
These L-FABP-negative foci are correlated with a higher
growth potential. Consequently, the FABP-expression
was measured as a parameter for HCC-development.
Even after a relatively short period of DEN
Table 1 Average protein expression in DEN-treated liver determined with immunohistochemistry by measuring DAB-
positive staining
Inside tumour
16W 20W 25W 30W
Av (%) SEM p Av (%) SEM p Av (%) SEM p Av (%) SEM p
TIE2 0,75 0,68 NS 8,81 2,52 NS 13,24 1,53 < 0,01 9,17 1,84 NS
VEGF 6,74 2,09 < 0,05 16,91 3,28 < 0,001 27,72 3,42 < 0,001 33,50 8,16 < 0,01
HIF1-a 3,79 0,57 < 0,001 5,49 0,48 < 0,001 7,63 0,37 < 0,001 11,47 0,50 < 0,001
CD105 6,29 2,88 NS 10,40 1,70 < 0,001 15,08 1,44 < 0,001 12,57 1,75 < 0,001
F4/80 3,12 0,30 < 0,001 5,70 1,25 < 0,001 6,16 0,46 < 0,001 3,21 0,30 < 0,001
Surrounding tumour
16W 20W 25W 30W
Av (%) SEM p Av (%) SEM p Av (%) SEM p Av (%) SEM p
TIE2 0,36 0,68 NS 12,35 2,37 < 0,05 17,63 2,52 < 0,01 13,30 2,89 < 0,05
VEGF 8,06 2,09 < 0,01 10,35 1,92 < 0,001 26,56 4,23 < 0,001 30,01 7,39 < 0,001
HIF1-a 1,51 0,70 < 0,01 1,43 0,17 < 0,001 1,67 0,19 < 0,001 3,20 0,17 < 0,001
CD105 5,17 2,49 NS 13,68 0,88 < 0,001 17,14 1,77 < 0,001 21,94 3,24 < 0,001
F4/80 5,82 0,37 < 0,001 10,78 0,50 < 0,001 13,92 0,72 < 0,001 10,24 0,98 < 0,001
Non-tumour
16W 20W 25W 30W
Av (%) SEM p Av (%) SEM p Av (%) SEM p Av (%) SEM p
TIE2 4,77 1,75 NS 4,33 1,36 NS 3,90 0,62 NS 2,95 0,83 NS
VEGF 4,50 0,88 NS 2,80 0,73 NS 4,19 0,85 NS 8,72 1,60 < 0,01
HIF1-a 1,04 0,16 < 0,01 0,38 0,12 NS 0,98 0,19 < 0,01 2,53 0,08 < 0,001
CD105 3,74 0,68 NS 6,06 0,74 < 0,05 5,36 0,48 < 0,001 4,40 0,31 < 0,05
F4/80 0,87 0,27 NS 1,62 0,37 < 0,05 2,43 0,28 < 0,01 1,44 0,16 < 0,01
P-values were calculated for the difference with healthy liver protein levels.
Figure 8 Left: mean intercapillary distances at different time points,*** = p < 0,001, right: measurement of ICD.
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Figure 9 Top: PET-images of mice at 30 weeks, static reconstruction of a 30 min acquisition; Bottom: normalised counts of F[18]MCH
uptake during a follow-up study.
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administration (16W) significant decrease in FABP-
expression is seen compared to controls. After 25W
DEN large FABP-negative lesions appear throughout the
liver, alternating with small FAPB-positive regions, while
control tissue showed a homogenous expression.
DEN-injections also gave rise to increased inflamma-
tion, confirmed by H&E staining, as well as F4/80 which
is a marker for Kuppfer cells. Activation of Kupffer cells
leads to the release of cytokines, reactive oxygen species,
and platelet activating factors, which are involved in the
Figure 10 Top: 3D reconstructions of vascular corrosion castings, Middle: SEM-images of venous vascular corrosion castings; Bottom:
SEM-images of arterial vascular corrosion castings.
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angiogenic switch. Furthermore, the chronic inflamma-
tion causes hepatocyte damage, leading to fibrosis as
seen on the sirius red staining. In our study we show
that Tie2 is up-regulated in the fibrotic matrix sur-
rounding the HCC-lesions, which was also characterised
by increased macrophage infiltration, confirming Tie2’s
correlation with hepatic inflammation. In addition, Tie2
is a receptor for angiopoetins, which play an important
role in angiogenesis. Furthermore, the presence of fibro-
sis creates an increased intrahepatic vascular resistance
and impairs oxygen diffusion, resulting in hypoxia which
is the onset for the angiogenic switch. This is supported
by our findings HIF1a and VEGF levels were increased
in the fibrotic non-HCC tissue after DEN-treatment.
The increased expression of HIF1a inside tumour
nodules, confirms the vast oxygen need of the malignant
hepatocytes. To fulfil that requirement, tumour cells
start expressing angiogenic factors, such as VEGF and
PlGF, inducing the angiogenic switch.
Up till now, VEGF was one of the key targets in
angiogenesis research, but recently PlGF gained interest
because its association with pathological conditions.
PlGF levels are known to be elevated in a variety of can-
cers [28-33] and is associated with poor prognosis in
HCC [34]. The up-regulation of PlGF in this DEN-
model supports the theory that PlGF plays an essential
role in the angiogenesis of HCC. Protein levels of
sVEGFR1, an important inhibitor for VEGF and PlGF,
did not significantly alter, suggesting that the increase of
angiogenic factors was physiologically relevant. Thus,
the increase of angiogenic factors (VEGF, PlGF and
Tie2), resulted in an increased neovascularisation. The
IHC results of the CD105-staining revealed a low
CD105 expression in the normal endothelial cells of the
liver and was up-regulated in the malignant liver lesions
at 20W, consistent with previous studies [17]. The inter-
capillary distances significantely decreased after 25W
DEN, verifying neovascularisation; although an increase
was seen at 30W supporting the theory that malignant
hepatocytes tend to outgrow their vascular supply and
become accostumed to hypoxia. This up-regulation of
CD105 was more prominent around HCC-lesions,
Figure 11 Left: sprouting angiogenesis; Right: intussusceptive angiogenesis.
Figure 12 Left: protein concentrations in liver tissue, determined by ELISA; Right: protein concentrations in serum, determined by
ELISA. Asterisks (*) represent the significant P-value of the difference between DEN-treated groups and controls. (* = p < 0,05, ** = p < 0,01,
*** = p < 0,001).
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suggesting that the newly formed vessels form a circum-
ferential mantle around the tumours. This was con-
firmed by the CT-reconstructions of the vascular casts.
SEM-images demonstrate the presence of neo-angiogen-
esis, by visualising budding and intussusceptive angio-
genesis. Furthermore, the images illustrate the overall
microvascular abnormality of DEN-treated livers. Thus,
the combination of casting and micro-CT imaging pro-
vides unique data on the hepatic circulation and neovas-
cularisation. It allows to digitally visualise the complex
architecture of the liver blood vessels and to provide
high resolution data for qualitative morphological
analysis.
During this study we have established a new mouse
model for HCC, which is considerably faster than cur-
rent chemically induced models and has the advantage
of tumour progression occurring in a background of
inflammation and fibrosis. Furthermore, angiogenic fac-
tors were assessed at different time points, to provide
important information about the kinetic changes of
angiogenic factors during HCC progression. Moreover,
several innovative imaging techniques were applied, not
only to assess tumour growth, but also to provide
further insight in microvascular alterations HCC livers.
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